Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Key Laboratory of Organ Transplantation, Ministry of Education, Ministry of Public Health, Chinese Academy of Medical Sciences, China.
Transplantation. 2019 Nov;103(11):2388-2396. doi: 10.1097/TP.0000000000002618.
Using pediatric donors for single-kidney transplantation (SKT) can increase the number of possible recipients. However, it is unclear when SKT involving small pediatric donors and adult recipients can safely be performed without compromising graft outcome.
From 2013 to 2017, a total of 102 SKTs in adult recipients were performed in our center using pediatric donors aged <12 years. We compared the outcomes from donors aged 8 to 36 months (the small-kidney group [SKG], n = 46) and from donors aged 3 to 12 years (the big-kidney group [BKG], n = 56). The median follow-up time was 30 months in the SKG and 28 months in the BKG.
All patients achieved satisfactory renal function after transplantation, despite the fact that some patients (SKG, 19.6%; BKG, 28.6%) developed delayed graft function. One-year graft survival and death-censored graft survival in the SKG were 89.1% and 100%, respectively, comparable to the results in the BKG (92.9% and 98.2%). One year later, the graft and patient survival rates in both groups remained unchanged. Pulmonary infection was the main cause of death in patients with a functioning graft (SKG, 4 patients; BKG, 2 patients). Proteinuria occurred early in some patients (SKG, 30.4%; BKG, 19.6%) and decreased gradually within the first year posttransplantation.
SKT from pediatric donors aged 8 to 36 months to selected adult recipients produced excellent intermediate-term outcomes, comparable with those when older pediatric donors were used. This study provides evidence to support a lower age limit for SKT from pediatric donors.
使用儿科供者进行单肾移植(SKT)可以增加可能的受者数量。然而,对于使用<12 岁儿科供者进行 SKT 而又不影响移植物结局的情况,目前尚不清楚何时可以安全进行。
2013 年至 2017 年,我们中心共对 102 例成人受者进行了 SKT,供者年龄<12 岁。我们比较了 8 至 36 月龄(小供肾组[SKG],n=46)和 3 至 12 岁(大供肾组[BKG],n=56)供者的结果。SKG 的中位随访时间为 30 个月,BKG 为 28 个月。
尽管部分患者(SKG,19.6%;BKG,28.6%)发生延迟性移植物功能不全,但所有患者在移植后均获得了满意的肾功能。SKG 的 1 年移植物存活率和受者死亡率分别为 89.1%和 100%,与 BKG 相似(分别为 92.9%和 98.2%)。1 年后,两组的移植物和受者存活率保持不变。有功能移植物的患者中,肺部感染是死亡的主要原因(SKG,4 例;BKG,2 例)。部分患者(SKG,30.4%;BKG,19.6%)早期出现蛋白尿,且在移植后 1 年内逐渐减少。
来自 8 至 36 月龄儿科供者的 SKT 用于选择性成人受者可获得极好的中期结果,与使用年长儿科供者时相似。该研究为支持 SKT 采用较小年龄的儿科供者提供了证据。